Omega Therapeutics Management
Management criteria checks 2/4
Omega Therapeutics' CEO is Mahesh Karande, appointed in Jun 2019, has a tenure of 5.08 years. total yearly compensation is $1.68M, comprised of 34.5% salary and 65.5% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $222.48K. The average tenure of the management team and the board of directors is 1 years and 3.3 years respectively.
Key information
Mahesh Karande
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 34.5% |
| CEO tenure | 5.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | less than a year |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Mar 31Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?
Feb 28
Omega Therapeutics: The Next Weight Loss Drug Runner
Jan 16Omega Therapeutics: Starting 2024 With A Bang
Jan 10Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Aug 04Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Jul 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$92m |
| Dec 31 2023 | US$2m | US$579k | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$108m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$108m |
| Dec 31 2022 | US$4m | US$556k | -US$103m |
| Sep 30 2022 | n/a | n/a | -US$93m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$75m |
| Dec 31 2021 | US$5m | US$512k | -US$68m |
| Sep 30 2021 | n/a | n/a | -US$57m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$939k | US$483k | -US$29m |
Compensation vs Market: Mahesh's total compensation ($USD1.68M) is above average for companies of similar size in the US market ($USD702.33K).
Compensation vs Earnings: Mahesh's compensation has been consistent with company performance over the past year.
CEO
Mahesh Karande (50 yo)
5.1yrs
Tenure
US$1,675,727
Compensation
Mr. Mahesh Karande serves as Director of Ashvattha Therapeutics, Inc. from May 2023. He serves as Director at KSQ Therapeutics, Inc. since December 2022. He serves as President, Chief Executive Officer and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$1.68m | 0.21% $ 222.5k | |
| Principal Financial Office | less than a year | no data | 0.068% $ 71.2k | |
| Chief Scientific Officer | 5yrs | US$1.32m | no data | |
| Senior Vice President of Investor Relations & Corporate Affairs | less than a year | no data | no data | |
| Chief People Officer | 1.5yrs | no data | no data | |
| VP and Head of Computational Genomics & Data Sciences | 2.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data |
1.0yrs
Average Tenure
55yo
Average Age
Experienced Management: OMGA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.1yrs | US$1.68m | 0.21% $ 222.5k | |
| Independent Director | 4.5yrs | US$151.29k | 0% $ 0 | |
| Independent Chairman of Board | less than a year | US$135.55k | 0% $ 0 | |
| Independent Director & Scientific Advisor | 6.9yrs | US$265.18k | 1.34% $ 1.4m | |
| Independent Director | 5.1yrs | US$153.68k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$148.68k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.3yrs | US$149.19k | 0% $ 0 | |
| Independent Director | less than a year | US$97.51k | 0% $ 0 |
3.3yrs
Average Tenure
64yo
Average Age
Experienced Board: OMGA's board of directors are considered experienced (3.3 years average tenure).